TY - JOUR
T1 - SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020–2023
AU - PARIS Study Group
AU - Carreño, Juan Manuel
AU - Wagner, Abram L.
AU - Monahan, Brian
AU - Singh, Gagandeep
AU - Floda, Daniel
AU - Gonzalez-Reiche, Ana S.
AU - Tcheou, Johnstone
AU - Raskin, Ariel
AU - Bielak, Dominika
AU - Morris, Sara
AU - Fried, Miriam
AU - Yellin, Temima
AU - Sullivan, Leeba
AU - Sordillo, Emilia Mia
AU - Gordon, Aubree
AU - van Bakel, Harm
AU - Simon, Viviana
AU - Krammer, Florian
AU - Amanat, Fatima
AU - Arunkumar, Guha Asthagiri
AU - Capuano, Christina
AU - Ehrenhaus, Jordan
AU - Fabre, Shelcie
AU - Hernandez, Matthew M.
AU - Jiang, Kaijun
AU - Lerman, Brian
AU - McMahon, Meagan
AU - Stadlbauer, Daniel
AU - Tan, Jessica
AU - Teo, Catherine
AU - Twyman, Kathryn
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.
AB - Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.
UR - http://www.scopus.com/inward/record.url?scp=85198366173&partnerID=8YFLogxK
U2 - 10.1038/s41467-024-50052-2
DO - 10.1038/s41467-024-50052-2
M3 - Article
C2 - 38992013
AN - SCOPUS:85198366173
SN - 2041-1723
VL - 15
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5847
ER -